发布时间：2025-03-03 14:05 New data on Nemluvio (nemolizumab), including an oral e-poster presentation characterizing the impact of Nemluvio in different pruriginous lesion types in prurigo nodularis from the phase III OLYMPIA program, and post-hoc analyses exploring the continuous response of Nemluvio up to 56 weeks in atopic dermatitis patients from the ARCADIA 1&2 trials and long-term extension study who had partial or no disease response at week 16
The latest data from the phase III READY-4 and phase IIIb RELAX studies of ready-to-use liquid neuromodulator Relfydess (RelabotulinumtoxinA), which has previously demonstrated a six-month clinical effect and rapid onset from day one for frown lines and crow’s feet, in the phase III READY clinical trial program1-3
Updates on Restylane and Sculptra, including data from a study exploring the benefits of Restylane Lyft or Contour with Sculptra in patients with medication-driven weight loss with associated facial volume loss, as well as
=*=*=*=*=*=
当前为第1/13页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页